Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Hypertension. 2015 Oct 5;66(6):1227–1239. doi: 10.1161/HYPERTENSIONAHA.115.06370

Figure 4.

Figure 4

Blocking p38 MAPK signaling attenuates experimental PH. Rats were treated with the p38 MAPK inhibition (SB203580) starting at the time of SU administration. A, B, Animals were monitored by echocardiography weekly. C, D, Hemodynamic measurements were done at week 3. RVSP measurements in DMSO, SU, and p38 MAPK inhibition treatment groups were assessed at week 3 post-SU. RV hypertrophy (RVH) measurements as assessed by the RV/LV+S weight ratios. E, Survival of rats after treatment was compared with DMSO and SU rats. (n=6 per group). Data are expressed as means ± SEM. (*: p<0.05) The experiments were repeated three times.

HHS Vulnerability Disclosure